AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Grant

Awarded By

Total Award Amount

  • 10000.00

    • Direct Costs

  • 7353.00

    • Sponsor Award Id

    • Contributor

  • Aman Wadhwa   Investigator  
  • Ana Xavier   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator